Albany Molecular Research Inc. (AMRI) Reports Q1 EPS Loss of $0.02, Posts Q2 and FY11 Guidance
Tweet
Share
E-mailGet Alerts AMRI Hot Sheet
Join SI Premium – FREE
Albany Molecular Research Inc. (NASDAQ: AMRI) reported Q1 EPS of ($0.02), $0.12 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $56.9 million versus the consensus estimate of $46.91 million.
Albany Molecular Research Inc. sees FY2011 revenue of $43-$46 million, versus the consensus of $50.57 million.
Albany Molecular Research Inc. sees FY2011 revenue of $179-$187 million, versus the consensus of $211.25 million.
Albany Molecular Research Inc. sees FY2011 revenue of $43-$46 million, versus the consensus of $50.57 million.
Albany Molecular Research Inc. sees FY2011 revenue of $179-$187 million, versus the consensus of $211.25 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
- Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
